Brokerages expect that Mediwound Ltd (NASDAQ:MDWD) will post earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Mediwound’s earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.11). Mediwound reported earnings per share of ($0.11) in the same quarter last year, which indicates a negative year-over-year growth rate of 27.3%. The company is expected to issue its next earnings report on Tuesday, November 12th.
On average, analysts expect that Mediwound will report full-year earnings of ($0.33) per share for the current fiscal year, with EPS estimates ranging from ($0.66) to $0.08. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.54) per share, with EPS estimates ranging from ($0.62) to ($0.45). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Mediwound.
Mediwound (NASDAQ:MDWD) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%. The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $7.03 million.
NASDAQ:MDWD opened at $3.01 on Friday. Mediwound has a 1-year low of $2.55 and a 1-year high of $6.75. The company has a 50-day moving average of $3.16 and a 200 day moving average of $4.23. The company has a quick ratio of 3.99, a current ratio of 4.13 and a debt-to-equity ratio of 0.11.
A number of large investors have recently added to or reduced their stakes in MDWD. ARK Investment Management LLC purchased a new stake in Mediwound in the second quarter worth about $325,000. Menta Capital LLC lifted its position in shares of Mediwound by 200.2% during the first quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29,686 shares during the last quarter. Delek Group Ltd. purchased a new stake in shares of Mediwound during the first quarter valued at about $141,000. Marshall Wace LLP purchased a new stake in shares of Mediwound during the first quarter valued at about $93,000. Finally, Millennium Management LLC lifted its position in shares of Mediwound by 33.2% during the fourth quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 17,048 shares during the last quarter. 30.78% of the stock is owned by institutional investors.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Article: How do candlesticks reflect price movement?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.